Immunotech Biopharm Ltd (SEHK: 6978)
Health Care · Biotechnology · CN
HK$0.39
+5.41% today · -92.4% 1Y
Immunotech Biopharm Ltd (SEHK: 6978) operates in the Biotechnology industry within the Health Care sector. The company is valued at $30.72M and employs 183 people.
Over the last twelve months the share price has lost 92.4%, trading between 0.33 and 5.83.
Tweenvest scores Immunotech Biopharm Ltd across four factors: quality 10/100. Its strongest factor is quality.
6978 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $30.72M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.28
- Dividend yield
- —
- Beta (5Y)
- 0.12
- 52-week high
- HK$5.83
- 52-week low
- HK$0.33
- Avg volume (3M)
- —
- Shares outstanding
- 617.50M
- Employees
- 183
- Next earnings
- —
About Immunotech Biopharm Ltd
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
- ISIN
- KYG4721A1004
- Founded
- 2006
- Listed since
- Jul 10, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.32 | +0.30% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.15 | -0.16% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.32 | +1.08% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.71 | +0.63% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.82 | +13.63% |
Figures last refreshed Aug 18, 2026.